Document is current
Any future updates will be listed below
-
Authors
Mäenpää, Niina
Tiainen, Leena
Hämäläinen, Mari
Luukkaala, Tiina
Tanner, Minna
Lahdenperä, Outi
Vihinen, Pia
Karihtala, Peeter
Kellokumpu-Lehtinen, Pirkko-Liisa
Moilanen, Eeva
Jukkola, Arja
-
Funding
Funding for this research was provided by:
Tampere University
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 28 February 2024
First Online: 11 March 2024
Declarations
:
: The Ethics Committee of Tampere University Hospital approved the original phase II clinical trial protocol (R08142M). The trial identifier is NCT00979641. All the patients that participated in the study gave their written informed consent.
: Not applicable.
: N.M. has received funding (grants) from Tampere University Hospital. L.T., M.T., P.K. and A.J. participated in an industry-sponsored clinical trial supported by Roche. P.K. is a member in an advisory board for Roche. A.J. is a member in an advisory board for Lilly. O.L. reports being consultant for Herantis Pharma. P.V. has received research funding from Eschner´s Foundation, consulting or advisory honoraria from Merck, Bristol-Myers Squibb, Ipsen, Novartis, and Roche, speakers’ bureau honoraria from Merck, Roche, and Bristol-Myers Squibb. M.H., T.L., P-L.K-L. and E.M. have no conflict of interests to declare.
